- In April 2022, Cadila Pharmaceuticals Limited announced the launch of novel three-dose recombinant nano-particle based rabies G protein vaccine. Unlike previous regimens, which require five doses spaced over 28 days, it is a three-dose vaccine administered in 50 microgram doses on days 0, 3, and 7. ThRabis is a vaccine produced with Virus-Like Particle technology (VLP)
